Manufacturing has been widely recognized as a bottleneck to bring advanced cell and gene therapies to the patients and families in need. The question is, should organizations stay the course internally, or look externally for their manufacturing needs?
Co-hosted by Informa Pharma Intelligence, this panel discussion will provide key inputs to consider when choosing between a make vs. buy, to scale-up manufacturing internally or look to an external supplier like a CDMO. We will hear from industry experts on the state of the advanced therapy industry, the investment that is pouring into advanced therapies, why manufacturing is such a critical component, various approaches to the build or buy decision and advantages and challenges of the decision.
The panel discussion will be followed by an interactive Q&A session.
After participation, you will:
- Understand the key factors that a cell and gene therapy should consider when deciding between scaling up manufacturing internally or using an external supplier
- Appreciate the state of the advanced therapy industry and why we need to resolve the manufacturing bottleneck to bring advanced medicines to the patients and families who need them
- Recognize that both solutions, build or buy, have their advantages and challenges and perhaps a hybrid solution may be the best approach.